Literature DB >> 10772940

Increased intracellular triglyceride in C(2)C(12) muscle cells transfected with human lipoprotein lipase.

P Poirier1, T Marcell, P U Huey, I R Schlaepfer, G C Owens, D R Jensen, R H Eckel.   

Abstract

Much of the knowledge about the cell biology of lipoprotein lipase (LPL) in vitro has been gained from adipose tissue model systems. However, the importance of skeletal muscle lipoprotein lipase (SMLPL) to both lipoprotein and muscle metabolism remains unclear. Although the production of LPL in cultured myocytes has been documented, the amount of enzyme activity produced is small. To develop a more suitable tissue culture model for SMLPL, mouse C(2)C(12) myoblasts were stably transduced with a retroviral vector encoding the full-length human LPL (hLPL) cDNA. Control cells were transduced with a vector encoding beta-galactosidase. LPL expression was assayed as a function of cell growth by measuring LPL activity on days 3, 7, 9, 11, and 14 after subculture. The hLPL-transduced myoblasts increasingly overexpressed both heparin-releasable (HR) and intracellular (IN) LPL activity compared to nontransduced myoblasts (P < 0.001 at Day 11) and myoblasts transduced with the control vector (P < 0.001 at Day 11). This increase occurred while LPL mRNA levels remained stable between days 3 and 14. As expected, IN LPL activity was also increased in the transduced cells. High levels of LPL activity were also obtained after differentiating the C(2)C(12) cells into myotubes by serum deprivation. Additionally, throughout the time course, C(2)/LPL cells had greater amounts of intracellular triglyceride than both the C(2)C(12) and the C(2)/beta-GEO cells (P = 0.005 and P < 0.001, respectively) with the largest differences seen on day 14 of the time course (P = 0.001, C(2)/LPL vs C(2)C(12) (r) or C(2)/beta-GEO cells). Thus, C(2)C(12) myoblasts stably transduced with hLPL markedly overexpressed both HR and IN LPL activity compared to control cells which, in turn, was associated with increases in intracellular triglyceride content. Because LPL regulation in tissues is mostly posttranslational, this new in vitro model will permit the in-depth study of the posttranslational regulation of SMLPL and provide new insights into the fate of lipoprotein-derived fatty acids in muscle. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10772940     DOI: 10.1006/bbrc.2000.2528

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

1.  Fatty acids increase glucose uptake and metabolism in C2C12 myoblasts stably transfected with human lipoprotein lipase.

Authors:  Warren H Capell; Isabel R Schlaepfer; Pamela Wolfe; Peter A Watson; Daniel H Bessesen; Michael J Pagliassotti; Robert H Eckel
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-07-13       Impact factor: 4.310

2.  Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy.

Authors:  Valerie Ferreira; Jaap Twisk; Karin Kwikkers; Eleonora Aronica; Diane Brisson; Julie Methot; Harald Petry; Daniel Gaudet
Journal:  Hum Gene Ther       Date:  2014-02-28       Impact factor: 5.695

3.  Angiopoietin-like 4 mediates PPAR delta effect on lipoprotein lipase-dependent fatty acid uptake but not on beta-oxidation in myotubes.

Authors:  Marius R Robciuc; Paulina Skrobuk; Andrey Anisimov; Vesa M Olkkonen; Kari Alitalo; Robert H Eckel; Heikki A Koistinen; Matti Jauhiainen; Christian Ehnholm
Journal:  PLoS One       Date:  2012-10-04       Impact factor: 3.240

4.  Skeletal muscle damage and impaired regeneration due to LPL-mediated lipotoxicity.

Authors:  K P Tamilarasan; H Temmel; S K Das; W Al Zoughbi; S Schauer; P W Vesely; G Hoefler
Journal:  Cell Death Dis       Date:  2012-07-19       Impact factor: 9.685

5.  Intramyocellular lipids of muscle type in athletes of different sport disciplines.

Authors:  Yoshinao Nakagawa; Masaaki Hattori
Journal:  Open Access J Sports Med       Date:  2017-07-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.